Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. is a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection), the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.